Project description:To determine the distribution of centromere units in the genome of holocentric Chionographis japonica, we performed CENH3-ChIPseq using the customized species-specific CENH3 antibody. We mixed the chromatins of C. japonica and Secale cereal (inbred line Lo7) to dilute the highly abundant centromeric Chio satellite repeats (16%) in the C. japonica genome before immunoprecipitation. In addition, to determine the large-scale genome organization, we performed ChIPseq by targeting the evolutionarily conserved eu- and heterochromatin-specific histone marks H3K4me2 and H33K9me2
2023-05-08 | GSE228407 | GEO
Project description:Whole genome shotgun sequences of Chionographis japonica
| PRJEB58128 | ENA
Project description:Long-read PacBio Sequencing of Chionographis japonica
| PRJEB58125 | ENA
Project description:RNA-Seq Analyses of Chionographis japonica
| PRJEB58123 | ENA
Project description:Enzymatic Methyl-Seq of Chionographis japonica
| PRJEB58127 | ENA
Project description:Chromosome Conformation Capture (Hi-C) sequencing of Chionographis japonica
| PRJEB58124 | ENA
Project description:Large-scale genome architecture and chromatin composition of holocentromeric plant Chionographis japonica
| PRJEB58432 | ENA
Project description:CENH3-ChIPSeq, H3K4me2-ChIPSeq and H3K9me2-ChIPSeq of Chionographis japonica
Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
